- Home
- SFWL vs SRZN Comparison
SFWL vs SRZN Comparison
Compare SFWL & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFWL
- SRZN
- Stock Information
- Founded
- SFWL 2001
- SRZN 2015
- Country
- SFWL China
- SRZN United States
- Employees
- SFWL N/A
- SRZN N/A
- Industry
- SFWL Trucking Freight/Courier Services
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- SFWL Industrials
- SRZN Health Care
- Exchange
- SFWL Nasdaq
- SRZN Nasdaq
- Market Cap
- SFWL 82.3M
- SRZN 85.6M
- IPO Year
- SFWL 2023
- SRZN N/A
- Fundamental
- Price
- SFWL $1.03
- SRZN $11.46
- Analyst Decision
- SFWL
- SRZN Strong Buy
- Analyst Count
- SFWL 0
- SRZN 2
- Target Price
- SFWL N/A
- SRZN $38.50
- AVG Volume (30 Days)
- SFWL 16.6K
- SRZN 14.8K
- Earning Date
- SFWL 09-04-2025
- SRZN 08-08-2025
- Dividend Yield
- SFWL N/A
- SRZN N/A
- EPS Growth
- SFWL 4.79
- SRZN N/A
- EPS
- SFWL 0.13
- SRZN N/A
- Revenue
- SFWL $504,158,000.00
- SRZN $12,621,000.00
- Revenue This Year
- SFWL N/A
- SRZN N/A
- Revenue Next Year
- SFWL N/A
- SRZN N/A
- P/E Ratio
- SFWL $7.88
- SRZN N/A
- Revenue Growth
- SFWL 24.75
- SRZN N/A
- 52 Week Low
- SFWL $0.86
- SRZN $5.90
- 52 Week High
- SFWL $1.60
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- SFWL 53.17
- SRZN 64.58
- Support Level
- SFWL $1.05
- SRZN $10.90
- Resistance Level
- SFWL $1.07
- SRZN $11.73
- Average True Range (ATR)
- SFWL 0.05
- SRZN 0.92
- MACD
- SFWL -0.00
- SRZN 0.10
- Stochastic Oscillator
- SFWL 17.65
- SRZN 90.00
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. Through its subsidiaries, it offers contract logistics services in China. The contract logistics services offered by the company include planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).